Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC : Episode 3
Opinion
Video
Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations
Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.
EP: 1.The State of Targeted Therapies in NSCLC
EP: 2.Frontline Treatments for KRAS G12C-Mutation mNSCLC
Now Viewing
EP: 3.Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations
EP: 4.The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC
EP: 5.Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition
EP: 6.Disease Progression Beyond Frontline KRAS G12C Inhibitors
EP: 7.CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC
EP: 8.KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC
EP: 9.Practical Management of Hepatotoxicity in KRAS G12C Inhibitors
EP: 10.Future Perspectives in KRAS G12C-Mutated NSCLC
Related Videos
Related Content
